InspireMD, Inc.

Analysis for Ticker: NSPR

Inspiremd Inc is a medical technology company that develops carotid stents like CGuard Prime to prevent strokes, but its internal mathematics has transformed it into a wealth extraction engine that is collapsing under its own weight. The company is attempting to sell 75,0$ million of new common stock through a broker named BTIG, which is a disaster for investors because of a hidden rule triggered by the stock price. Because the shares are trading at 1,15$, which is well below the 1,38$ threshold, a full-ratchet trapdoor has opened for the owners of Series C preferred stock. This rule forces the company to print and hand over extra shares for free to these preferred holders to make up for the lower price, creating a loop where every new sale triggers more free shares and further dilutes the value of everyone else. To keep this fire burning, they authorized an increase in their share limit from 150 million to 250 million shares. This emergency is the result of a multi-year destruction of capital that began long before the death spiral. By 12/2023, the business lost 19,9$ million, a figure that accelerated to a 32,0$ million loss by 12/2024. By 09/2025, the company generated only 5,8$ million in revenue and 1,4$ million in gross profit, while its operating expenses ballooned to 38,9$ million. During this same period, they burned 25,7$ million in pure cash and handed out 9,4$ million in stock to employees and directors. By 12/2025, the total accumulated deficit reached 290,5$ million, forcing the leadership to admit in writing that there was substantial doubt the company could survive another twelve months. Large investment funds including Marshall Wace, OrbiMed, Nantahala, and Rosalind Advisors sat at the extraction point, holding over 44 million pre-funded warrants that could be turned into shares for almost nothing.